Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients allowing women to live longer or remain disease-free for longer if the medicines are given before and after surgery as well as in advanced stages of disease.

    Key data being presented include:

    - Herceptin before surgery: Results from the NOAH (NeOAdjuvant Herceptin)
      phase III study showed that women with locally advanced HER2-positive
      breast cancer who started a combination of Herceptin and standard
      chemotherapy prior to surgery had a significantly greater chance of
      living free of their disease (event-free survival) three years after
      initiation of treatment as compared to women who were receiving pre-
      operative chemotherapy alone.

    - Xeloda in early breast cancer: Early data from an independent study in
      Finland and Sweden indicate that the chemotherapy pill Xeloda, which is
      already proven in advanced breast cancer, may also reduce the
      recurrence of early breast cancer and help women live longer. This is
      one of 20 Xeloda abstracts that have been accepted for presentation
      during SABCS.

    - Avastin in advanced breast cancer: First efficacy results from the
      largest ever safety study of Avastin in a real-life setting, which
      involved more than 2,000 patients with locally recurrent or metastatic
      breast cancer, confirm that Avastin can be used with a broad range of
      chemotherapy treatments giving patients a median of almost 10 months
      without their disease getting worse. The results, which are one of 24
      separate Avastin data presentations during SABCS, confirm that Avastin
      based therapy is essential for improving the lives of women with
      advanced breast cancer.

"Researching new cancer treatments is a complex step by step process. Each success helps lay the foundation for the next step forward," said William M. Burns, CEO Division Roche Pharmaceuticals. "These results show that we are making significant progress towards giving doctors and their breast cancer

patients better and more effective treatment options to fight this devastating disease at all stages," he added.

    Presentation of Data


    Gianni L et al  Neoadjuvant trastuzumab in patients with   Friday 12th,
                    HER2-positive locally advanced breast      December
                    cancer: primary efficacy analysis of the   09:30 hrs
                    NOAH trial                                 General
                                                               Session 3
                                                               (Hall D)


    Joensuu H et    Significant improvement in                 Sunday 14th,
    al. for The     recurrence-free survival (RFS)             December
    Finnish Breast  when capecitabine (X) is                   11:45 hrs
    Cancer Group    integrated into docetaxel (T)              General
                    5-FU + epirubicin + cyclophosphamide       Session 7
                    (CEF) adjuvant therapy for high-risk
                    early breast cancer (BC): interim
                    analysis of the FinXX-trial.


    Smith IE et al  Primary analysis of study MO19391, an      Saturday
                    open-label safety study of bevacizumab     13th,
                    plus taxane-based therapy as 1st-line      December
                    treatment of patients with locally         07:00 hrs
                    recurrent or metastatic breast cancer.     Poster
                                                               Session 4

The above mentioned studies and data represent the latest results of clinical research for each treatment and are not necessarily part of the indicated licence in each country. For detailed label information, visit the website of your health authority or the EMEA website

Note to Editors

Breast cancer is the most common cancer among women worldwide.(i) Each year more than one million new cases of breast cancer are diagnosed worldwide, and nearly 400,000 people will die of the disease annually. (ii) In HER2- positive breast cancer, increased quantities of the HER2 protein are present on the surface of the tumour cells. This is known as 'HER2-positivity'. High levels of HER2 are present in a particularly aggressive form of the disease which responds poorly to chemotherapy. Research shows that HER2-positivity affects approximately 20-30 percent of women with breast cancer.(iii)

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the

central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at

    All trademarks used or mentioned in this release are legally protected.



    (i) World Health Organization,

    (ii) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and
         Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress,
         Lyon, 2004. 2004.

    (iii) Harries M, Smith I. The development and clinical use of trastuzumab
          (Herceptin). Endocr Relat Cancer 9: 75-85, 2002.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
(Date:11/25/2015)... 2015  Today AVACEN Medical announced the issue of United States patent ... Adjustment ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific ... Photo - ... ... ...
(Date:11/25/2015)... YORK , November 25, 2015 ... market of self-monitoring blood glucose devices was valued at ... grow with a CAGR of 5.7% during 2015 - ... geriatric population and increasing prevalence of diabetes. In addition, ... diabetes care is also contributing to the growth of ...
(Date:11/25/2015)... Pennsylvania , November 25, 2015 - ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) --> ... Care Continuing Medical Education (CME) ... medical information products and services, will feature latest diagnostic imaging textbooks ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor ... Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension (PH) ... nominated by the public, will receive special recognition throughout 2016 as part of ...
(Date:11/25/2015)... ... 25, 2015 , ... Privately owned Contract Development and Manufacturing ... its current state of the art research, development and manufacturing facility outside of ... manufacturing capacity as well as to support its clients’ growing research and development ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of ... weight gain, cold hands, and dry skin. But many people who find their cholesterol ... exercise regimen instead of their thyroid, especially if they don’t have any of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
Breaking Medicine News(10 mins):